Amyloid antibodies in practice: Only 6 percent with symptomatic ARIA

Alzheimer's therapy Amyloid antibodies in practice: Only 6 percent with symptomatic ARIA

Initial data from a US memory care clinic show that very few people undergoing Alzheimer's therapy with lecanemab develop symptomatic cerebral edema or microbleeds. Early treatment significantly reduces the risk.